Efficacy, Safety, and Tolerability of Laquinimod in Relapsing Remitting Multiple Sclerosis

- Multiple Sclerosis
- Completed

Study Title: The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Teva Identifier: LAQ-MS-305 | 2012-003647-30

ClinicalTrials.gov Identifier: NCT01707992

Study Status: Completed

Trial Condition(s): Multiple Sclerosis

Interventions: Drug: Laquinimod | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial

Participation criteria and map of study locations

Key Participation Requirements

Gender: Female, Male

Age group: Adult

Age Range: 18 Years to 55 Years

Trial Duration: February 20, 2013 - July 4, 2017

Phase: Phase 3

Study Type

Interventional